You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

270 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Cetuximab with Irinotecan - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Jun 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
Mar 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant, Curative, Palliative
Aug 2021
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Aug 2021
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022

Pages